Novo Nordisk stock news
Novo Nordisk announced positive topline results from the PIONEER TEENS Phase 3a clinical trial, evaluating oral semaglutide for the treatment of type 2 diabetes in children and adolescents aged 10–17. The trial demonstrated a statistically significant and superior reduction in HbA1c of 0.83% compared to placebo at 26 weeks, while maintaining a safety profile consistent with the broader semaglutide portfolio. The company expects to file for regulatory label expansion for the Ozempic® pill and Rybelsus® in the U.S. and EU in the second half of 2026, potentially establishing the first oral GLP--1 receptor agonist therapy for this demographic.